A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

The comedian has taken her followers along for the ride as she's experimented with different weight-loss drugs to find what ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events.

Ventyx Biosciences, Inc. surged after strong Phase 2 results for VTX3232 in obesity. Click for key insights and what VTYX ...

London-based startup SheMed, which offers personalized weight-loss plans using popular medicines Wegovy and Mounjaro, said on Thursday it has raised $50 million in its Series A funding round to expand ...

Semaglutide is a so-called GLP-1 drug: a hormone mimicker meant to treat type 2 diabetes. Our bodies secrete natural GLP-1 hormones after we eat to help start insulin production, which regulates blood ...

Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...

Prescription-drug costs were the top-cited factor for rising premiums, according to large businesses surveyed by the think tank. Two-thirds of large businesses said GLP-1s for weight loss had a ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...